Charles River Laboratories Intl (CRL)
$167.51 6.13 (3.53%)
18:30 EST CRL Stock Quote Delayed 15 Minutes
Previous Close $167.51
Market Cap 8.03B
PE Ratio 63.21
Volume (Avg. Vol.) 412,737
Day's Range 166.04 - 168.79
52-Week Range 123.17 - 179.38
Dividend & Yield N/A (N/A)
CRL Stock Predictions, Articles, and Charles River Laboratories Intl News
- From InvestorPlace
- From the Web
Charles River Labs (NYSE:CRL) is ranked as a Strong Buy using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. CRL has been upgraded from a Buy to a Strong Buy in the last week.
The 50%-plus gains in Charles River Laboratories year-to-date might scare off some investors, but CRL stock still looks to have upside.
The ratings of 5 Life Sciences Tools & Services stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
This week, the ratings of 6 Life Sciences Tools & Services stocks on Portfolio Grader are down. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
The grades of 4 Life Sciences Tools & Services stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").
4 Life Sciences Tools & Services stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an "A" ("strong buy") or "B" overall ("buy").
Technical strength and promising seasonality makes these names look like short-term stocks to buy for tactical investors.
Healthcare stocks rose 0.5% on Wall Street on Friday.
Healthcare stocks finished up 0.3% on Wall Street today.
Healthcare stocks finished up 4.3% on Wall Street today.
Healthcare stocks declined on Wall Street today, down 4.3%.
Healthcare stocks declined on Wall Street on Thursday, down 2.3%.
Healthcare stocks declined on Wall Street on Tuesday, down 0.8%.
Healthcare stocks rose broadly on Wall Street on Monday, with the sector seeing an overall increase of 0.8%.
Healthcare stocks finished down broadly on Wall Street today, with the sector seeing an overall decline of 0.2%.
Healthcare stocks advanced broadly on Wall Street on Friday morning, with the sector seeing an overall increase of 0.4%.
Healthcare stocks advanced 1.2% on Wall Street on Thursday morning.
Healthcare stocks declined on Wall Street so far on Thursday, down 0.2%.
From Simply Wall St
Some Charles River Laboratories International, Inc. (NYSE:CRL) shareholders may be a little concerned to see that the Corporate Executive VP & CFO, David Smith, recently sold a whopping US$766k worth<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/this-insider-has-just-sold-shares-in-charles-river-laboratories-international-inc-nysecrl/">Read More...</a></div>
From Analyst Ratings
Today it was reported that a Director at Charles River Labs (CRL – Research Report), Robert Bertolini, exercised options to sell 7,170 CRL shares at $55.17 a share, for a total transaction value of $1.22M. Following Robert Bertolini’s last CRL Sell transaction on March 02, 2017, the stock climbed by 84.7%. This is Bertolini’s first
From Analyst Ratings
In a report released yesterday, Jack Meehan from Barclays maintained a Hold rating on Charles River Labs (CRL – Research Report), with a price target of $170.00. The company’s shares closed last Monday at $173.32, close to its 52-week high of $175.25. According to TipRanks.com, Meehan is a 4-star analyst with an average return of
Navellier RatingsPowered by Portfolio Grader